Cargando…

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

BACKGROUND: Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoint molecules should be developed. For the first t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fabian, Kellsye P, Padget, Michelle R, Donahue, Renee N., Solocinski, Kristen, Robbins, Yvette, Allen, Clint T., Lee, John H., Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Schlom, Jeffrey, Hodge, James W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247398/ https://www.ncbi.nlm.nih.gov/pubmed/32439799 http://dx.doi.org/10.1136/jitc-2019-000450

Ejemplares similares

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
por: Jochems, Caroline, et al.
Publicado: (2016)

Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020)

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
por: Robbins, Yvette, et al.
Publicado: (2020)

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
por: Wolfson, Benjamin, et al.
Publicado: (2021)

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12
por: Franks, S. Elizabeth, et al.
Publicado: (2023)

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
por: Daly, John, et al.
Publicado: (2022)

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
por: Kowalczyk, Joshua T, et al.
Publicado: (2022)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
por: Dahut, Madeline, et al.
Publicado: (2023)

Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
por: Tumino, Nicola, et al.
Publicado: (2021)

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
por: Cassetta, Luca, et al.
Publicado: (2020)

PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation
por: Tumino, Nicola, et al.
Publicado: (2019)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

CAR-NK Cells Targeting Sars-Cov-2 Glycosites As COVID-19 Treatment
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function
por: Trikha, Prashant, et al.
Publicado: (2021)

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022)

Allelic variation of KIR and HLA tunes the cytolytic payload and determines functional hierarchy of NK cell repertoires
por: Philippon, Camille, et al.
Publicado: (2023)

Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
por: Renken, Stefanie, et al.
Publicado: (2022)

NK cells CD56(bright) and CD56(dim) subset cytokine loss and exhaustion is associated with impaired survival in myeloma
por: Seymour, Frances, et al.
Publicado: (2022)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
por: Ghonim, Mohamed A, et al.
Publicado: (2021)

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
por: Fenerty, Kathleen E., et al.
Publicado: (2018)

Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
por: Fenerty, Kathleen E., et al.
Publicado: (2019)

Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells
por: Hoke, Austin T.K., et al.
Publicado: (2021)

GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post–allo-HSCT
por: Wang, Dongyao, et al.
Publicado: (2022)

Hank Williams
por: Jordá, Eduardo
Publicado: (1992)

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management
por: Marté, Jennifer L, et al.
Publicado: (2020)

GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
por: Caforio, Matteo, et al.
Publicado: (2021)

Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
por: Shin, Eunju, et al.
Publicado: (2023)

TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
por: Slattery, Karen, et al.
Publicado: (2021)

Therapeutic Targeting Steroid Resistant Pro-Inflammatory NK and NKT-Like Cells in Chronic Inflammatory Lung Disease
por: Hodge, Greg, et al.
Publicado: (2019)

Affinity, potency, efficacy, and selectivity of neurokinin A analogs at human recombinant NK2 and NK1 receptors
por: Rupniak, Nadia M. J., et al.
Publicado: (2018)

Hank : el sello de la impunidad
por: Ruanova Zárate, Felipe
Publicado: (1995)

STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
por: Nakamura, Takashi, et al.
Publicado: (2021)

IMMU-02. Targeted innovative antibody fragment-based immunotherapy for medulloblastoma
por: Niesen, Judith, et al.
Publicado: (2022)

NK Cells as Potential Targets for Immunotherapy in Endometriosis
por: Ścieżyńska, Aneta, et al.
Publicado: (2019)

IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
por: Desbois, Mélanie, et al.
Publicado: (2020)

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
por: Schmidt, Dayane, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ip0ij0tnvs4ptu18s4ghr6q2vn